AirDuo Respiclick inhalation powder, Teva Respiratory, 232 mcg / 14 mcg, metered dose inhaler, 6 count, NDC 59310-0822-06
Fluticasone propionate / Salmeterol xinafoate inhalation powder, Teva
Respiratory, 113 mcg / 14 mcg, metered dose inhaler, 1 count, NDC
00093-3608-82
Reason for the Shortage
Teva Respiratory did not provide a reason for the shortage.
Other fluticasone and salmeterol dry powder inhalers are not affected by the shortage.
Available Products
AirDuo Respiclick inhalation powder, Teva Respiratory, 113 mcg / 14 mcg, metered dose inhaler, 6 count, NDC 59310-0812-06
AirDuo Respiclick inhalation powder, Teva Respiratory, 55 mcg / 14 mcg, metered dose inhaler, 1 count, NDC 59310-0805-06
Fluticasone propionate / Salmeterol xinafoate inhalation powder, Teva
Respiratory, 232 mcg / 14 mcg, metered dose inhaler, 1 count, NDC
00093-3609-82
Fluticasone propionate / Salmeterol xinafoate inhalation powder, Teva
Respiratory, 55 mcg / 14 mcg, metered dose inhaler, 1 count, NDC
00093-3607-82
Estimated Resupply Dates
Teva Respiratory has AirDuo Respiclick fluticasone 232 mcg/salmeterol 14
mcg on back order and the company estimates a release date of
mid-October 2019.
Teva Respiratory has fluticasone 113 mcg/salmeterol 14 mcg on back order
and the company estimates a release date of mid-October 2019.pirbuterol
Updated
Updated October 8, 2019 by Rachael Freeman, PharmD, BCPS. Created March
7, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. © 2019,
Drug Information Service, University of Utah, Salt Lake City, UT.
DISCLAIMER
This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin.
